PLUS1
3.7599
-0.2401 (-6.0%)
-0.2401 (-6.0%)
Upgrade to Real-Time
Market Closed
Best deals to access real time data! |
|
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
|
|
Canna Trader Pro
Monthly Subscription
for only
|
|
Small Cap Basic
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| CytoDyn Inc (QB) | CYDY | OTCMarkets | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded  |
|
|---|---|---|---|---|
| -0.2401 | -6.0% | 3.7599 | 16:59:03 |
| Close Price | Low Price | High Price | Open Price | Previous Close |
|---|---|---|---|---|
| 3.7599 | 3.51 | 4.02 | 3.84 | 4.00 |
| Bid Price | Ask Price | Spread | News | |
|---|---|---|---|---|
| 3.78 | 3.85 | 0.07 | 1 | - |
| Stock Trades | Traded Volume | VWAP | Dollar Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 7,011 | 7,538,763 | $ 3.7623 | $ 28,363,421 | 7,325,072 | 0.261 - 10.01 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 16:00:08 | formt | 101 | $ 3.75 | USD |
CytoDyn (QB) Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 2.13B | 565.93M | 302.11M | $ - | $ - | - | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| 9.58M | $ - | 0.00% | - | - |
CytoDyn (QB) News
| Date | Time | Source | News Article |
|---|---|---|---|
| 8/14/2020 | 17:19 | Edgar (US Regulatory) | Annual Report (10-k) |
| 7/31/2020 | 17:21 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 7/24/2020 | 16:34 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 7/08/2020 | 17:07 | Edgar (US Regulatory) | Additional Proxy Soliciting Materials (definitive) (defa14a) |
| 7/08/2020 | 16:31 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 6/19/2020 | 17:19 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 6/08/2020 | 19:24 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CYDY Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 4.54 | 5.09 | 3.51 | 4.35 | 6,057,504 | -0.7801 | -17.18% |
| 1 Month | 5.40 | 6.75 | 3.51 | 5.14 | 6,028,482 | -1.64 | -30.37% |
| 3 Months | 3.17 | 10.01 | 2.67 | 5.13 | 7,708,635 | 0.5899 | 18.61% |
| 6 Months | 1.18 | 10.01 | 0.81 | 3.82 | 7,089,367 | 2.58 | 218.64% |
| 1 Year | 0.4338 | 10.01 | 0.261 | 3.18 | 4,504,086 | 3.33 | 766.74% |
| 3 Years | 0.69 | 10.01 | 0.0552 | 2.87 | 1,715,981 | 3.07 | 444.91% |
| 5 Years | 0.81 | 10.01 | 0.0552 | 2.71 | 1,121,928 | 2.95 | 364.19% |
CytoDyn (QB) Description
| CytoDyn Inc. is a late-stage biotechnology company developing innovative treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. Leronlimab is in a class of therapeutic monoclonal antibodies designed to address unmet medical needs in the areas of Human Immunodeficiency Virus (HIV), Cancer, and Immunology. |
